The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 12, 2023
Filed:
May. 17, 2021
Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase
Vanderbilt University, Nashville, TN (US);
The Uab Research Foundation, Birmingham, AL (US);
The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);
Matthew Hall, Damestown, MD (US);
Daniel J. Urban, Poolesville, MD (US);
John Knight, Birmingham, AL (US);
Ross Holmes, Birmingham, AL (US);
Kyle David Wood, Birmingham, AL (US);
Alex Waterson, Nashville, TN (US);
Victor M. Darley-Usmar, Birmingham, AL (US);
Leonard M. Neckers, Bethesda, MD (US);
VANDERBILT UNIVERSITY, Nashville, TN (US);
THE UAB RESEARCH FOUNDATION, Birmingham, AL (US);
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Bethesda, MD (US);
Abstract
The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amound of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R, R, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.